UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 221

Sortiert nach

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

The New England journal of medicine, 1995-11, Vol.333 (22), p.1437-1444

1995

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

The American journal of cardiology, 2002-11, Vol.90 (10), p.1084-1091

2002

Link zum Volltext

Verfügbarkeit prüfen

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

Annals of internal medicine, 2002-12, Vol.137 (11), p.875

2002

Link zum Volltext

Verfügbarkeit prüfen

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study

JAMA : the journal of the American Medical Association, 2003-04, Vol.289 (14), p.1826

2003

Link zum Volltext

Verfügbarkeit prüfen

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

Diabetes care, 1998-08, Vol.21 (8), p.1288

1998

Link zum Volltext

Verfügbarkeit prüfen

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

Arteriosclerosis, thrombosis, and vascular biology, 1995-05, Vol.15 (5), p.678

1995

Link zum Volltext

Verfügbarkeit prüfen

The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day

The American journal of cardiology, 1997-01, Vol.79 (1), p.38-42

1997

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients

The American journal of cardiology, 1998-08, Vol.82 (3), p.311-316

1998

Link zum Volltext

Verfügbarkeit prüfen

Effects of simvastatin, an HMG‐CoA reductase inhibitor, in patients with hypertriglyceridemia

Clinical cardiology (Mahwah, N.J.), 2003-01, Vol.26 (1), p.18-24

2003

Link zum Volltext

Verfügbarkeit prüfen

The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study

Clinical therapeutics, 1996-09, Vol.18 (5), p.853-863

1996

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of Atorvastatin for Reducing Low-Density Lipoprotein Cholesterol to National Cholesterol Education Program Treatment Goals

The American journal of cardiology, 1997-08, Vol.80 (3), p.347-348

1997

Link zum Volltext

Verfügbarkeit prüfen

Alendronate in early postmenopausal women : Effects on bone mass during long-term treatment and after withdrawal

The journal of clinical endocrinology and metabolism, 2000-04, Vol.85 (4), p.1492-1497

2000

Link zum Volltext

Verfügbarkeit prüfen

Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial

Archives of internal medicine (1960), 2003-10, Vol.163 (19), p.2277

2003

Link zum Volltext

Verfügbarkeit prüfen

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

Obstetrical & gynecological survey, 1996-04, Vol.51 (4), p.238-241

1996

Link zum Volltext

Verfügbarkeit prüfen

The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin

PharmacoEconomics, 1998-07, Vol.14 (1), p.59-70

1998

Link zum Volltext

Verfügbarkeit prüfen

Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal 1

The journal of clinical endocrinology and metabolism, 2000-04, Vol.85 (4), p.1492-1497

2000

Link zum Volltext

Verfügbarkeit prüfen

Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal1

The journal of clinical endocrinology and metabolism, 2000-04, Vol.85 (4), p.1492-1497

2000

Link zum Volltext

Verfügbarkeit prüfen

Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density1

The journal of clinical endocrinology and metabolism, 2000-02, Vol.85 (2), p.720-726

2000

Link zum Volltext

Verfügbarkeit prüfen

Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density 1

The journal of clinical endocrinology and metabolism, 2000-02, Vol.85 (2), p.720-726

2000

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

JAMA : the journal of the American Medical Association, 1996-01, Vol.275 (2), p.128

1996

Link zum Volltext

Verfügbarkeit prüfen

Hypopituitarism following head trauma

American journal of obstetrics and gynecology, 1977-03, Vol.127 (6), p.678-679

1977

Link zum Volltext

Verfügbarkeit prüfen

The origins of SARS-CoV-2: A critical review

Cell, 2021-09, Vol.184 (19), p.4848-4856

2021

Link zum Volltext

Verfügbarkeit prüfen

Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo

Journal of virology, 2020-10, Vol.94 (21)

2020

Link zum Volltext

Verfügbarkeit prüfen

AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2021-06, Vol.160 (7), p.2496-2508

2021

Link zum Volltext

Verfügbarkeit prüfen

Methods for handling missing binary data in substance use disorder trials

Drug and alcohol dependence, 2023-09, Vol.250, p.110897-110897, Article 110897

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 221

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(209)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(166)
Life Sciences & Biomedicine
(116)
Humans
(102)
Biological And Medical Sciences
(51)
Female
(50)
Male
(50)
Medical Sciences
(41)
Adult
(39)
Physical Sciences
(38)
Middle Aged
(37)
Technology
(33)
Aged
(29)
Animals
(24)
Pharmacology. Drug Treatments
(23)
Chemistry
(20)
Cardiac & Cardiovascular Systems
(19)
Cardiovascular System & Cardiology
(19)
Materials Science
(18)
Materials Science, Multidisciplinary
(18)
Science & Technology - Other Topics
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day

Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients

Effects of simvastatin, an HMG‐CoA reductase inhibitor, in patients with hypertriglyceridemia

The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study

Effectiveness of Atorvastatin for Reducing Low-Density Lipoprotein Cholesterol to National Cholesterol Education Program Treatment Goals

Alendronate in early postmenopausal women : Effects on bone mass during long-term treatment and after withdrawal

Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin

Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal 1

Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal1

Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density1

Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density 1

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

Hypopituitarism following head trauma

The origins of SARS-CoV-2: A critical review

Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo

AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

Methods for handling missing binary data in substance use disorder trials

Suchergebnisse filtern